Accurate Risk Assessment for the Development of PML in Natalizumab Treated MS Patients Requires CSF Analysis

Peggy Bettin, Jerry Lin, and Saud A. Sadiq. Presented at the 2012 annual meeting of the American Academy of Neurology, held April 23-27 in New Orleans, LA.

Read Abstract

Abstract Date

April 23, 2012

Abstracts archive


Tisch MS Research Center of New York

521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900

Privacy Policy


Support Tisch MS

Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.